Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

BACKGROUND: The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Madhav Prasad, Ballal, Sanjana, Bal, Chandrasekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365580/
https://www.ncbi.nlm.nih.gov/pubmed/30725219
http://dx.doi.org/10.1186/s13550-019-0484-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365580/
https://www.ncbi.nlm.nih.gov/pubmed/30725219
http://dx.doi.org/10.1186/s13550-019-0484-y

Ejemplares similares